Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00HPD
|
|||
| Former ID |
DNCL003374
|
|||
| Drug Name |
Moxetumomab pasudotox
|
|||
| Synonyms |
CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Hairy cell leukaemia [ICD-11: 2A82.2; ICD-10: C91.4; ICD-9: 202.4] | Approved | [1] | |
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
AstraZeneca
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | Modulator | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 761104. | |||
| REF 2 | Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies | |||
| REF 3 | Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.